ArticleCancer innovation2022

Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer.

Society of Clinical Research of Oncology Medications of China Anticancer Association et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.